It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in this work illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications.

This book reviews recent knowledge of the role of gut microbiome in health and disease. It covers extensive topics for several diseases, including metabolic-related diseases, allergies, gastrointestinal diseases, psychiatric diseases, and cancer, while also discussing therapeutic approaches by microbiota modification. Comprehensive and cutting-edge, Gut Microbiome-Related Diseases and Therapies deepens a reader's theoretical expertise in gut microbiome. Graduate and postdoctoral students, medical doctors, and biomedical researchers will benefit from this book.

The 7 chapters in this book have been selected from the contents of the Oncological Imaging section in Grainger & Allison's Diagnostic Radiology 6e. These chapters provide a succinct up-to-date overview of current imaging techniques and their clinical applications in daily practice and it is hoped that with this concise format the user will quickly grasp the fundamentals they need to know. Throughout these chapters, the relative merits of different imaging investigations are described, variations are discussed and recent imaging advances are detailed. Please note that the following chapters represent a portion of the oncological imaging aspects in the comprehensive 6th edition of Grainger's & Allison's Diagnostic Radiology (for example, abdominal tumours are considered in section C "Abdominal Imaging")

As bone marrow transplant treatments and chemotherapy develop, the population of neutropenic cancer patients is on the rise. These developments are allowing patients to live longer, but in recent years, they have also led to an increase in previously rare infections and syndromes, whose management is unfamiliar to the average healthcare professional. Infections in Neutropenic Cancer Patients is a crucial resource for medical students, residents, practitioners, health professionals, and researchers. It details the clinical presentation, diagnoses, and management of an array of common infections and syndromes specific to neutropenic cancer patients, including real scenarios accompanied by color photos and radiographic results. Chapters include step-by-step tutorials, access to clinical answers on diagnosis and treatment, and a tabulated summary of the key points.

The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.

This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

This issue of Hematology/Oncology Clinics of North America is devoted to Head and Neck Cancer. Guest Editor Alexander Colevas, MD has assembled a group of expert authors to review the following topics: Epidemiology of SCCHN; Genetics of Head and Neck Cancers; Molecular Biology of Head and Neck Cancers; Quality of Life in Head and Neck Cancer Treatment; Nasopharyngeal Carcinoma; Evolving Surgical Techniques in SCCHN; Radiation Oncology New Approaches in SCCHN; Thyroid Gland Malignancies; Sequential and Concurrent Chemoradiation; Systemic Chemotherapy for SCCHN Focus on New targets and Agents; EGFR Inhibition in SCCHN; Diagnostic and Therapeutic Assessment Imaging in Head and Neck Cancer; Salivary Gland Cancers; Immunotherapy in SCCHN; Human Papillomavirus in SCCHN; and Supportive Care Issues in SCCHN Treatment and Survivorship: Dental, Nutrition, Speech and Swallowing, Depression.

This book shares the latest research and practice-oriented findings in medical sciences with a wide audience. It addresses a range of contemporary issues, often unresolved or contentious, across various medical fields, including advances in the management of hemorrhagic brain stroke. It also discusses metastatic renal cell carcinoma - a global scourge with an extremely poor long-term survival prognosis, the course and sequelae of renal cell carcinoma, as well as advances in targeted molecular therapy with sunitinib, a receptor tyrosine kinase inhibitor. Further, it examines the molecular targeting of proliferative signaling of the epidermal growth factor receptor in the first-line treatment of patients with metastatic non-small-cell lung cancer. Other articles cover clearance of toxins in hemodialyzed patients; the search for diagnostic and therapeutic markers in the connective tissue disease scleroderma; obesity linked to inappropriate dietary habit; clinical problems related to the diagnosis of sensitization to fungi and its role in asthma; and reasons for the perilous trend of avoiding basic vaccinations in children. Lastly, the book explores the rapid developments in e-health technologies that increase access to health services, particularly for the elderly. The book is intended for clinical specialists, researchers, and all allied health professionals from various fields.

Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity provides the reader with a basic understanding on how the ovary is adversely impacted by cancer treatment, an essential foundational knowledge for this rapidly-developing field. The book describes both the clinical and laboratory approaches to discovering the potentially adverse effects of cancer treatment on the ovary, also laying out possible preventative approaches and future directions for the field. Clinicians working in the field of reproductive biology and oncology will find an essential reference that provides the necessary tools to assess the reproductive toxicological effects of cancer treatments.

The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.

This issue of Hematology/Oncology Clinics of North America is devoted to Congenital and Acquired Disorders of Macrophages and Histiocytes. Guest Editors Nancy Berliner, MD and Barrett Rollins, MD have assembled a group of expert authors to review the following topics: Nosology of Langerhans Cell Histiocytosis (LCH); Cell of Origin of LCH; Genomic Changes in LCH; Clinical Treatment of LCH; Neurodegeneration in LCH; Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH); Familial HLH; HLH in Adults; Macrophage Activation Syndrome; and Stem Cell Transplant for HLH.

This volume provides insight into the pivotal roles of stem cells, exosomes and other microvesicles in biofunction and molecular mechanisms and their therapeutic potential in translational nanomedicine. It further highlights evidence from recent studies as to how stem cell derived exosomes and microRNAs may restore and maintain tissue homeostasis, enable cells to recover critical cellular functions and begin repair regeneration. These early studies in animal models of aging also show evidence of improved immune, cardiovascular and cognitive functions as well as improved health span and life span. The use of exosomes from body fluids to define specific biomarkers for various tumors may also clear the path to patient-targeted treatments by developing exosome-derived microRNA based cancer therapeutics. It is essential reading for graduate students, research fellow and biomedical researchers in academia or the pharmaceutical or biotech industries.

This invaluable resource discusses insights ranging from basic biological mechanisms of various types of stem cells through the potential applications in the treatment of human diseases, including cancer and genetic disorders. These discoveries are placed within the structural context of tissue and developmental biology in sections dealing with recent advances in understanding different types of stem cell biology and their potential applications in tissue repair and regeneration and in the treatment different types of human cancer and genetic diseases or disorders. Stem Cells for Cancer and Genetic Disease Treatment and the other books in the Stem Cells in Clinical Applicationsseries will be invaluable to scientists, researchers, advanced students and clinicians working in stem cells, regenerative medicine or tissue engineering as well as cancer or genetics research.

This issue of Surgical Oncology Clinics of North America, edited by Thomas Weber, MD, is devoted to Genetic Testing in Surgical Oncology. Articles in this issue include: The Critical Importance of Timely Genetic Testing; Securing and Documenting Cancer Family History in the Age of the Electronic Medical Record; Cancer Family Registries: Vital Tools for Patient Management and Cancer Genetics Translational Research; The Genetics of Breast Cancer; The Genetics of Colorectal Cancer: HNPCC, FAP MYH, and Hamartomatous Syndromes Including Peutz-Jeghers and Jevenile Polyposis; Hereditary Gastric Cancer Syndromes; Hereditary Pancreatic Cancer Syndromes; Hereditary Melanoma: Genetics and Multidisciplinary Management; Multiple Endocrine Neoplasia: Genetics and Clinical Management; Sequence Variants of Uncertain Significance (VUS): What To Do When Genetic Testing Results Are Not Definitive; Confidentiality and the Risk of Genetic Discrimination: What Surgeons Need to Know; and A Certified Genetic Counselor: A Crucial Clinical Resource in the Management of Patients with Suspected Hereditary Solid Tumor Syndromes.

This volume presents state of the art of methods that can be useful for both basic and translational researchers to conduct chemoprevention preclinical studies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cancer Chemoprevention: Methods and Protocols aims to ensure successful results in the further study of this vital field.

Cancers of the larynx, while survival outcomes increase, result in massive treatment damage from radiation and surgery. Patients often lose ability to speak and to eat. Preserving the larynx is a fine balance of cancer eradication, life extension, and quality of life. This issueof Otolaryngologic Clinics led by Dr Babak Sadoughi should be of interest to Otolaryngologists, Oncologists, Radiologists, and Speech Therapists. The issue approach reaches all the most important aspects of diagnosing and treating the patient with laryngeal cancer with a focus on preserving the voice in early laryngeal cancer and preserving and restoring function in advanced laryngeal cancer. Topics include: Functional Anatomy and Oncological Barriers of the Larynx; Evaluation of the Dysphonic Patient; Role of Advanced Laryngeal Imaging in Glottic Cancer; Laryngeal Function after Radiation Therapy; Management of Dysphonia after Radiation Therapy; Contemporary Surgical Management of Early Glottic Cancer; Voice Prognosis after Transoral Laser Microsurgery of the Larynx; Voice Rehabilitation after Transoral Laser Microsurgery of the Larynx; Quality of Life after Conservation Surgery for Laryngeal Cancer; Salvage Conservation Surgery of the Larynx; Airway Preservation in Ablative Laryngeal Surgery; Voice Restoration after Total Laryngectomy. A special article for Residents, written by a Resident, emphasizes essential "take home messages" for laryngeal function preservation diagnosis and treatment.

Drs. Robert J. Lewandowski and Matthew S. Davenport have assembled an expert panel of authors on the topic of Interventional Radiology. Articles will include: Abdominal Biopsy: Technical and Clinical Considerations; Intra-arterial Therapies for Liver Masses; Liver Ablation: Best Practice; Renal Intervention; Imaging (Findings) after Intervention; Assessing Imaging Response to Therapy; Liver Masses: Imaging Evaluation in Non-cirrhotics; Imaging in Cirrhotics: Current Evidence; Renal Masses: Imaging Evaluation; Adrenal Imaging/Intervention; The Pancreas; and more!

Cancer Screening and Genetics is reviewed extensively in this important Surgical Clinics of North America issue. Articles include: Cancer Genetics and Implications for Clinical Management; Epigenetics and Cancer; Screening and Early Detection of Cancer: Successes and Failures; Screening for Lung Cancer; Screening for Breast Cancer; Viral Hepatitis and Hepatocellular Cancer: How Should Patients Be Screened?; Screening for Pancreatic Cancer: Where Do We Stand?; Hereditary Colorectal Cancer: Genetics and Screening; Personalized Approach to Gastrointestinal Cancers; Screening for Colorectal Cancer; Screening for Prostate Cancer: Why the Controversy?; Gastric Cancer: East versus West-Is screening and early detection the difference?; and more!

The Integrated Control of Cell Proliferation and Cell Viability; G.I. Evan, et al. Control of Invasive Cell Growth by the MET Family Oncogenes; F. Galimi, P.M. Comoglio. Src Family Kinases and the Cell Cycle; S.A. Courtneidge. p16 Family Inhibitors of Cyclin-Dependent Kinases; Y. Li, et al. p53-Mediated Apoptosis: Regulatory and Mechanistic Aspects; Y. Haupt, et al. The Molecular Genetics of Wilms Tumor; J. Pelletier, et al. HTLV-1 Tax: A Paradigm for How a Single Auxiliary Factor Can Regulate the Expression of Viral and Cellular Genes; G. Perini, M.R. Green. CREM: Transcriptional Pacemaker of the cAMP Response; J.S. Lee, et al. MADS-domain transcription Factor and Their Accessory Proteins (TCFs): Nuclear Targets for Growth Control Signals; M.A. Cahill, et al. Retinoblastoma Protein, Gene Expression, and Cell Cycle Control; J.C. Azizkhan, et al. Cyclin A-kinase Binding to and Regulation of the Function of a Growth-Promoting Transcription Factor; W. Krek, et al. Homeostatic Mechanisms Governing the Go hase as Defined by the Gas Genes; C. Schneider, et al. The TEL Gene and Human Leukemias; T.R. Golub, et al. Characterization of the TCLI Gene and Its Involvement in T-Cell Malignancies; L. Virgilio, et al. 3 Additional Articles. Index.

This issue of Hematology/Oncology Clinics of North America is devoted to Pancreatic Cancer. Guest Editor Brian Wolpin, MD has assembled a group of expert authors to review the following topics: Biology and genetics of pancreatic adenocarcinoma; Mouse models of pancreatic adenocarcinoma; Epidemiology and inherited predisposition for sporadic pancreatic adenocarcinoma; Familial pancreatic adenocarcinoma; Imaging and endoscopic approaches to pancreatic cancer; Diagnosis and management of pancreatic cystic neoplasms; Surgical management of pancreatic cancer; Peri-operative therapy for surgically resectable pancreatic adenocarcinoma; Diagnosis and management of borderline resectable pancreatic adenocarcinoma; Treatment approaches to locally advanced pancreatic adenocarcinoma; Therapeutic approaches for metastatic pancreatic adenocarcinoma; Supportive and end-of-life care for patients with pancreatic adenocarcinoma; and Novel therapeutics for pancreatic adenocarcinoma.

This volume is essential for geneticists, molecular biologists, biochemists, and medical doctors interested in the use of mouse models in cancer research. Recent genome studies, together with refined genetic engineering techniques, have greatly increased the value of using mice for research on cancer and other human disorders. The chapters of this book will support scientists in choosing the most suitable mouse models for their research questions. The book provides detailed methodological information for genetic or chemical induction of different types of cancer, histomorphometric cancer analysis, and in vivo imaging, as well as protocols to investigate oncogene addiction, immune surveillance, and hallmarks of cancer such as angiogenesis or metastasis. Four review-like articles provide background information on mouse technologies and histopathologic differences between mouse and human cancers. The mouse models described in individual chapters will fuel the understanding of cancer initiation, immune system roles, tumor angiogenesis, invasion, metastasis, and the relevance of molecular diversity observed among human cancers. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and resourceful, Mouse Models of Cancers: Methods and Protocols, is a valuable laboratory resource for all researchers, from the graduate level upwards, who study cancer and new possibilities for its treatment.

This issue of Recent Results in Cancer Research presents a comprehensive review of current understanding of chromosomal instability in cancer and of strategies to use this information for better treatment of patients with cancer. Cancer is a disease of the chromosomes, and chromosomal instability in cancer disrupts gene function by either inactivating tumor suppressor genes or activating growth-promoting oncogenes. The chromosomal basis for these aberrations is either translocations, which change the integrity of genes, or abnormal numbers of chromosomes, a condition referred to as aneuploidy, which results in abnormal gene expression levels. Such structural or numerical chromosomal aberrations are specific for distinct tumor entities. The degree of chromosomal instability and the degree of intratumor heterogeneity have profound consequences for disease outcome and for therapeutic stratification.